Page last updated: 2024-11-04

tegafur and Hepatitis C

tegafur has been researched along with Hepatitis C in 3 studies

Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.

Research Excerpts

ExcerptRelevanceReference
"Oral tegafur/uracil therapy has been indicated for patients with hepatocellular carcinoma (HCC) and is often used as a single-agent treatment."7.79Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. ( Akizuki, S; Fushiya, N; Nishino, H; Ohnishi, A; Takagi, I, 2013)
"We report a case of complete remission of multiple hepatocellular carcinomas after oral administration of enteric-coated tegafur/uracil."7.70Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil. ( Asakura, H; Ebe, Y; Ichida, T; Ishikawa, T; Ishimoto, Y; Naito, M; Nomoto, M; Usuda, H; Yokoyama, J, 1999)
"Oral tegafur/uracil therapy has been indicated for patients with hepatocellular carcinoma (HCC) and is often used as a single-agent treatment."3.79Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. ( Akizuki, S; Fushiya, N; Nishino, H; Ohnishi, A; Takagi, I, 2013)
"We report a case of complete remission of multiple hepatocellular carcinomas after oral administration of enteric-coated tegafur/uracil."3.70Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil. ( Asakura, H; Ebe, Y; Ichida, T; Ishikawa, T; Ishimoto, Y; Naito, M; Nomoto, M; Usuda, H; Yokoyama, J, 1999)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fushiya, N1
Takagi, I1
Nishino, H1
Akizuki, S1
Ohnishi, A1
Yamashita, T2
Arai, K1
Terashima, T1
Sunagozaka, H1
Shimakami, T1
Mizukoshi, E1
Sakai, A1
Honda, M1
Kaneko, S1
Ishikawa, T1
Ichida, T1
Ishimoto, Y1
Yokoyama, J1
Nomoto, M1
Ebe, Y1
Usuda, H1
Naito, M1
Asakura, H1

Other Studies

3 other studies available for tegafur and Hepatitis C

ArticleYear
Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma.
    Anti-cancer drugs, 2013, Volume: 24, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Asian People; C

2013
[A case report of S-1 monotherapy for advanced hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:9

    Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Combinations; Fatal Outcome;

2012
Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil.
    The American journal of gastroenterology, 1999, Volume: 94, Issue:6

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr

1999